A patient in her mid-40s visited a medical facility for a pelvic sonography examination due to severe menorrhagia. Her recent history consisted of abnormal test results from a Pap smear five years earlier. A colposcopic examination was recommended, and the results revealed moderate to focally severe squamous cell dysplasia (CIN II-III). Cryotherapy was used to treat the lesion, and three months later, her follow-up colposcopy showed hyperplastic squamous epithelium but no definite dysplasia. A colposcopy was again recommended in four months' time. Unfortunately, there is no record in her file of a follow-up examination performed at that hospital site. A moderate amount of debris and fluid within the endometrial cavity was demonstrated on her most recent pelvic sonography examination. The endometrial cavity was distended to 4.0 × 2.2 × 3.7 cm, but there appeared to be no other myometrial abnormality. Both ovaries were normal. The debris and fluid were unlikely to represent a missed abortion because the patient had had a previous tubal ligation years earlier. Endometrial malignancy could This case report demonstrates an example of endometrial adenocarcinoma. The etiology of endometrial adenocarcinoma is not fully understood, and there are no current screening methods for early detection. Surgery remains the treatment of choice, and women with welldifferentiated tumors with little or no myometrial invasion have the best prognosis.
not be ruled out, and a follow-up sonography examination was recommended.
An Acuson Sequoia 512, with a curved-array 2to 6-MHz transducer, performed the 2D sonographic examination. The sonogram revealed that the patient had an enlarged uterus, measuring over 16 cm in length. The endometrial cavity had also increased in size, to 9.0 × 7.2 × 10.5 cm. Echogenic, mobile debris within the cavity surrounded a solid structure measuring 8.2 × 6.5 × 5.7 cm, which contained an inner, complex cystic area that measured 5 × 4.7 × 4.3 cm. The myometrium surrounding the structure had a thinned appearance, whereas the myometrium in the lower uterine segment appeared more normal (Figs. 1-2). The use of color Doppler demonstrated that the mass lacked vascularity. A computed tomography (CT) examination of the abdomen and pelvis was recommended and performed. The CT examination determined that the endometrial cavity contained a high density fluid. The cervix was enlarged and contained a 4-cm mass. No pelvic or retroperitoneal lymphadenopathy was seen. The patient also had small bilateral pleural effusions.
The patient then underwent biopsies of both the cervix and the endometrium. The cervical specimen contained well-differentiated invasive adenocarcinoma, which had an endometrioid morphologic pattern. The endometrial specimen contained well-differentiated invasive adenocarcinoma (possibly stage II) with endocervical tissue. Further tests needed to be performed to determine whether these were two separate carcinomas or one carcinoma that exhibited different morphologic growth features. The patient was referred to another medical facility for further treatment. Due to patient confidentiality, her record of treatment and outcome is unavailable. This report thus focuses only on the abnormal sonographic findings.
Discussion
Endometrial adenocarcinoma usually affects postmenopausal women. However, this disease is not excluded from premenopausal or younger women. [1] [2] [3] Although the etiology is not fully understood, several risk factors associated with this disease include obesity, chronic annovulation, nulliparity, diabetes mellitus, high blood pressure, characteristics of polycystic ovarian syndrome, endometrial hyperplasia, and inherited forms of colorectal cancer. 2, 3 The likelihood of developing endometrial adenocarcinoma is higher in patients who have a history of breast, ovarian, and nonhereditary colorectal cancer. There is currently no screening process for early detection of endometrial adenocarcinoma, and biopsy remains the only sure form of diagnosis. 3 Endometrial adenocarcinoma can metastasize via three routes: (1) by direct extension to adjacent structures, including the bladder and rectum; (2) by the lymphatic system to the pelvic lymph nodes, aortic lymph nodes, and ovaries; and (3) hematogenously to distant sites, including the lungs and liver. 4 Computed tomography and magnetic resonance imaging (MRI) are recommended preoperative procedures for endometrial adenocarcinoma. Computed tomography provides valuable information regarding lymphatic metastases, and MRI is helpful in evaluating the depth of myometrial invasion. In the past, patients were often advised to have preoperative radiation treatments. This is no longer considered advisable due to the loss of information concerning the depth of myometrial invasion. Standard therapy for endometrial adenocarcinoma includes a staging laparotomy, total abdominal hysterectomy, and a bilateral salpingooophorectomy. Once the uterus has been removed, the depth of myometrial invasion is determined. This will provide an estimation of probable extrauterine spread. If the myometrium has tumor invasion of 50% or more, a pelvic and paraaortic lymphadenectomy will be performed. Younger patients with this disease tend to have well-differentiated endometrial adenocarcinoma (grade 1) with minimal myometrial invasion (stage I). This makes the risk for lymph node metastasis low and the prognosis very good. 3 Local spread to the cervix (stage II) occurs in about 10% to 15% of women with endometrial adenocarcinoma. These tumors are at a higher risk for deeper myometrial invasion and pelvic lymph node metastasis but still generally have a good prognosis. 3, 4 Early studies advocated a radical hysterectomy for patients with stage II adenocarcinomas. However, a recent study reported that a radical hysterectomy offered no prognostic advantage and that this treatment required further investigation.
Clinical follow-up at regular intervals is strongly recommended. The Pap smear and tumor marker, serum CA-125 (an indicator of metastatic disease), have detected up to 95% of all recurrences. 3 There is still some debate about the value of postoperative radiation therapy and chemotherapy. The survival rate of early stage disease is good. Studies show no clear improvement in the survival rates of women who combined the operation with therapy. Patients with deep myometrial invasion and a higher hystology grade do seem to benefit from radiation therapy and/or chemotherapy, but further investigation is needed. 3, 4 For those patients who wish to preserve their fertility and pursue childbearing, primary hormonal therapy with progestins is an option. With the hope of a good prognosis, this therapy is only being offered to patients who have well-differentiated tumors with no myometrial invasion. 2, 5 It is also suggested that patients being screened for this therapy need to be tested for a normal level of serum CA-125. 2, 6 The average length of treatment required for an initial response is 3 months. 1, 5, 7 Some patients require a longer period of time before signs of tumor regression appear. The length of treatment for these patients generally lasts for 12 to 14 months. If patients do not respond within this time frame, they are encouraged to have a hysterectomy. 5, 7 The optimal dose and duration of conservative treatment is unknown. 1, 5, 7 There are cases of disease progression and recurrence within the groups of women who opted for the progestin therapy. 2, 3, 5, 7 Although progestin therapy does have a positive effect on endometrial adenocarcinoma, it needs to be noted that it can increase the risk of breast and cervical cancer. Patients are often encouraged to have a hysterectomy following delivery due to the high relapse rate. 3, 7 It is unfortunate to note that very few of the women who undergo progestin therapy actually give birth to viable, healthy infants. 2, 3 Patients wishing to pursue this form of treatment need to be informed and carefully consider the risks involved with this experimental therapy. 1, 3, 7 
Conclusion
There is a very good prognosis for women who have well-differentiated endometrial adenocarcinoma with no or little myometrial invasion. Current standard therapy includes a staging laparotomy, total abdominal hysterectomy, and a bilateral salpingooophorectomy. Conservative treatment is an option for younger patients who wish to pursue childbearing. The problems with conservative therapy include the possible progression of the disease during treatment, recurrence, and an undetermined optimal dose and length of treatment.
